Clinical trials
Liver Fibrosis clinical trials
Below are recruiting liver fibrosis clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03308916Recruiting
Screening for liver scarring risk using noninvasive tests
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
OdenseAges 30–75 - NCT06509230Recruiting
Predicting serious liver scarring in hepatitis B patients
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
Hangzhou, ZhejiangAges 18–60 - NCT07613827Enrolling by invitation
AI screening for fatty liver disease using CT scans
This study uses artificial intelligence to help doctors identify fatty liver disease from CT scans you may already be having. If eligible, you'll have some blood tests and possibly an ultrasound or MRI to confirm liver health, helping catch liver disease early.
Shenyang, LiaoningAges 18 years+ - NCT04971577RecruitingPhase 2/Phase 3
Simvastatin for alcohol-related liver scarring in stable adults
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
BarcelonaAges 18 years+ - NCT07588854Recruiting
Liver Stiffness Testing and Biopsy for Chronic Liver Disease
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
ShanghaiAges 18–80 - NCT05644717RecruitingPhase 4
Testing erugliflozin for fatty liver and diabetes control
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Peshawar, KPKAges 18–65 - NCT07271576Recruiting
Phycocyanin study for liver fibrosis and cirrhosis
This trial tests if phycocyanin (a natural blue pigment from spirulina) can help protect the liver and slow damage from fibrosis or cirrhosis. It may be an option if you have stable liver disease and are looking for supportive therapy.
HangzhouAges 18–75 - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06845345Enrolling by invitationPhase 4
Can a special diet or pills help liver health?
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
RotterdamAges 18–75 - NCT04429100Recruiting
Breath-hold MRI test to measure liver scar levels
This study tests an MRI technique that briefly holds your breath to measure how scarred your liver tissue is. It may help doctors better spot and track liver fibrosis (scarring).
Hong Kong, ShatinAges Any age - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75 - NCT06779058Recruiting
Liver stiffness testing for hepatitis B patients
This trial uses MR elastography (a special MRI) to measure liver stiffness and check for fibrosis (scarring) without a needle biopsy. It may help guide treatment for chronic hepatitis B.
Shenyang, LiaoningAges 18–80 - NCT05651724Recruiting
MASH screening study for people with diabetes or obesity
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
Brussels, Vlaams-brabantAges 18–75 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT05699018Recruiting
Screening people with liver scarring in primary care
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
AngersAges 40–80 - NCT06599918RecruitingPhase 2
Nicotinamide for liver scarring in fatty liver disease
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
BarcelonaAges 18–85 - NCT02206841Recruiting
Study to confirm fatty liver and build fibrosis test markers
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
SeoulAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Birmingham, AlabamaAges 18 years+ - NCT06819917Recruiting
Liver fibrosis test study for fatty liver disease
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
CopenhagenAges 18–75 - NCT06293378Recruiting
Sulfasalazine for liver fibrosis and cirrhosis
This study tests if sulfasalazine, a medicine already used for other conditions, is safe and helpful for people with liver scarring (fibrosis or cirrhosis). It is for patients with cirrhosis caused by certain liver diseases, like PBC, hepatitis B, hepatitis C, or alcohol use.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06463223Enrolling by invitation
Liver imaging study for children with obesity
This study uses MRI scans to look at the livers of children with obesity, to find early signs of liver problems. It may help doctors understand how to protect the liver in children.
Gothenburg, Västra Götaland CountyAges 9–14 - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Liver Fibrosis trials by city
Studies with a site in or near these metro areas.
Liver Fibrosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for liver fibrosis?
- Yes. Clin2 currently lists 75 recruiting liver fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.